Biotechnology
Commented by Fabian Lorenz on February 27th, 2025 | 07:10 CET
Elon Musk, Donald Trump, and the GOLD MARKET! Barrick Gold and First Nordic Metals are rising! Even Novo Nordisk shares are in a gold rush!
No gold in Fort Knox? This crazy theory is currently being fueled by Donald Trump and Elon Musk. To uncover the secrets of the US gold reserve location, the two best friends plan to visit the site in person soon. Meanwhile, price targets of USD 3,500 for the precious metal are doing the rounds. Even Barrick Gold's stock is rising! Can the giant really solve a big problem? First Nordic Metals appears to be a more promising gold investment. The Company is focused on the European gold mining region of the future. The stock is only just being discovered by the capital market, and it is showing a lot of momentum. Novo Nordisk is also part of the "gold rush". The Norwegians are making billions with their weight loss injection. Problems at a competitor are causing a price jump.
Read
Commented by Fabian Lorenz on February 26th, 2025 | 07:10 CET
Key Industry: Defense! Will Rheinmetall, Renk & Co. soon turn to dynaCERT? Stock Jump at Evotec?
A bombshell at Rheinmetall! The defense company is considering converting automotive supply plants into defense production. Previously, Hensoldt had already reached out to Continental employees. It seems that defense companies are rushing to aid the struggling automotive industry as a key industry and job engine – or perhaps to replace it. Tanks, howitzers, and other heavy vehicles have one thing in common: diesel engines. To improve the CO2 balance of these vehicles, it would be only logical for Rheinmetall and Co. to turn to dynaCERT. The Company offers a retrofittable, affordable solution for reducing emissions and fuel consumption. Evotec does not have to worry about its carbon footprint. Instead, the share is showing signs of life!
Read
Commented by Fabian Lorenz on February 20th, 2025 | 07:30 CET
Multiplier potential with AI newcomer NetraMark! Palantir and BioNTech in one share!
"Game changer!" "Quantum leap!" "Revolution!" Experts use numerous superlatives to describe the possibilities of Artificial Intelligence (AI) in medicine. What is certain is that AI offers tremendous potential to develop new medications faster and more cost-effectively. Pharmaceutical companies can save billions, and patients can be cured more quickly. The market for AI in medicine is expected to see significant double-digit growth rates in the coming years. NetraMark Holdings aims to profit from this megatrend. The AI specialist is on the verge of a breakthrough and is starting 2025 with a software update, an important partnership, and reinforcements in top management. The share price has jumped but remains a hidden gem and is anything but expensive. There is significant upside potential!
Read
Commented by Juliane Zielonka on February 19th, 2025 | 08:00 CET
Pharma in Focus: Bayer, BioNxt Solutions, Novo Nordisk – Market Expansion, Innovation Acceleration, and a Costly Breach of Trust
The pharmaceutical and biotech market is on the move. Bayer AG aims to win the hearts of 1.2 million Japanese patients suffering from heart failure with promising study data. A drug that has already been successful in 90 countries is to be given an additional benefit. The biotech company BioNxt Solutions is attracting attention with new personnel in the finance and business areas. Its innovative drug delivery solutions could significantly improve the quality of life for millions of patients with neurodegenerative or chronic diseases. The move to a state-of-the-art research facility could accelerate the development of the active ingredients in its pipeline. Unfortunately, Novo Nordisk faces a setback following an M&A: the billion-dollar acquisition of an antihypertensive therapy turns out to be a costly mistake.
Read
Commented by Armin Schulz on February 19th, 2025 | 07:10 CET
Bayer, Vidac Pharma, Pfizer – Dementia, cancer, obesity: The race for the billion-dollar markets
The pharmaceutical industry is in the throes of a major upheaval – it is no longer just about research but also about big money. Whoever is ahead now secures not only fame but, above all, extremely lucrative markets. Looking at how companies are currently driving forward mergers or acquiring startups, it is clear: The battle for the next blockbuster drugs has long since become a billion-dollar gamble. There is a lot of activity, especially in areas such as cancer, dementia, and obesity. Everyone wants to be the first to patent the golden active ingredient. We take a look at three companies that are researching the next blockbusters.
Read
Commented by Fabian Lorenz on February 13th, 2025 | 07:10 CET
ACQUISITION?! Renk, BioNTech, and Biotech Highflyer Vidac Pharma
Is Renk about to be taken over? Quite possible. The Company, known for its transmissions for the Leopard tank, has a new major shareholder. And it turns out to be none other than KNDS – the maker of the Leopard 2 tank. The Renk share price reacted with a jump of 10%. Is there more to come? Vidac Pharma is also frequently mentioned as a potential takeover candidate. Like BMW, the Company is working on a "new class". But in this case, it is to save human lives. To this end, last year's biotech highflyer aims to revolutionize cancer treatment. Experts believe that a multiplication of the share price is possible. BioNTech is also fighting cancer. In addition to its own research, the German company is strategically focusing on acquisitions. Another one has just been completed. What is next?
Read
Commented by Fabian Lorenz on February 10th, 2025 | 07:30 CET
BIOTECH stocks in RALLY MODE: Valneva, BioNxt Solutions, Evotec – BUY signal or correction?
After the 50% rally, the stock of BioNxt Solutions is currently consolidating. However, the next buy signal could be generated soon. There will likely be some exciting announcements this year and perhaps even a strategic partnership. The new R&D site in Munich will likely also attract attention for the innovative biotech company in Germany. After the catastrophic year, things have quieted down for the time being at Evotec. Or is it more that the air has been let out? After all, there is a lot of uncertainty about what skeletons might still be in the closet and how things should continue strategically. The stock market does not like that. In contrast, Valneva has had an impressive rally since mid-January. Last week, there was another big announcement. After 50%, is there more potential with the French company?
Read
Commented by Fabian Lorenz on February 4th, 2025 | 07:30 CET
OPPORTUNITIES in the Tariff Crash: TUI Facing a 50% Price Surge? Valneva Stock Strong! Multiplier with Desert Gold?
CAD 10 per ounce of gold. This is the current valuation of Desert Gold's resource - a real bargain with a gold price of over USD 2,800. There are good reasons why Desert Gold's share price should rise soon. Analysts even consider a multiplication of its value to be possible. Last week, Valneva showed just how quickly a stock can suddenly jump by 20% or more. Thanks to a multi-million dollar order from the US military, the downward trend in the share price has been broken. Are further price gains possible? Experts at TUI believe a 50% price jump is achievable. But is optimism ahead? Do these stocks offer opportunities in the tariff crash?
Read
Commented by Juliane Zielonka on January 31st, 2025 | 06:55 CET
Vidac Pharma, Bayer AG, Novo Nordisk: Three companies that will shape the pharmaceutical landscape in 2025
The pharmaceutical industry is again demonstrating its market power between innovation and risk: Vidac Pharma reports a milestone in colorectal cancer therapy with VDA1275. The combination of the active ingredient with a chemotherapeutic agent achieves a 38.9% tumor reduction in preclinical studies. This synergy effect raises hope for gentler chemotherapy treatments and more innovative approaches. Bayer AG is making waves at the JP Morgan Health Conference with its pharmaceutical pipeline: the prostate cancer drug Nubeqa™ achieves blockbuster status with revenue of EUR 1 billion. In women's health, the first non-hormonal therapy for menopausal symptoms is expected to reach the US market as early as 2025. Novo Nordisk, on the other hand, is threatened with a class-action lawsuit in the billion-dollar market for obesity drugs: the REDEFINE-1 study on the promising drug CagriSema revealed weaknesses in the study design. After the results were made public, the share price fell by 18%. While Vidac Pharma and Bayer impress with precise study results, the Novo Nordisk case shows the fragility of methodological fuzziness. The details.
Read
Commented by André Will-Laudien on January 27th, 2025 | 07:40 CET
Biotech - Here we go! 100% opportunities for Evotec, BioNxt, Bayer, Formycon, and Novo Nordisk!
Last week, the DAX 40 index reached a new all-time high of 21,520 points. At first glance, this sounds odd because half of the stocks are languishing at multi-year lows. However, the driving forces are the heavyweights SAP, Siemens, Allianz, Airbus, and Deutsche Telekom. They are pushing the index upward daily, putting ETF fund managers under pressure as they have to adjust the weightings accordingly. However, the more capital flows into the leading stocks, the more investors are looking for lagging stocks that could successfully turn the chart around due to operational turning points. We select a few opportunity stocks.
Read